EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants

Claire M Quinlan, Jerry Avorn, Aaron S Kesselheim, Daniel E Singer, Yichi Zhang, Alex Cervone, Kueiyu Joshua Lin

JAMA Internal Medicine · 2025

DOI: 10.1001/jamainternmed.2024.8335 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Internal Medicine, 2025. Verfasst von Claire M Quinlan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Rivaroxaban, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance People living with HIV and atrial fibrillation (AF) often receive anticoagulation that may interact with their antiretroviral therapy (ART). No studies exist comparing the safety of oral anticoagulants in this population.

Objective

To compare the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with AF and HIV. Design, Setting, and Participants A new-user, active-comparator, propensity score overlap-weighted cohort study using the target trial emulation framework including Medicare claims database data (January 1, 2013, to December 31, 2020) was carried out. The analysis was conducted from July 2023 to April 2024. Exposure New initiators of warfarin vs apixaban, rivaroxaban vs apixaban, and rivaroxaban vs warfarin aged 50 years or older with nonvalvular AF and HIV. Main Outcomes and Measures The primary outcome was hospitalization for major bleeding. Secondary outcomes included hospitalization for gastrointestinal bleeding, ischemic stroke, and all-cause mortality.

Results

Overall, 2683 individuals (mean [SD] age, 66.22 [8.97] years; 580 female individuals [21.6%]) in the warfarin vs apixaban cohort, 2176 (mean [SD] age, 66.61 [8.87] years; 455 female individuals [20.9%]) in the rivaroxaban vs apixaban cohort, and 1787 (mean age, 65.47 years; 377 female individuals [21.1%]) in the rivaroxaban vs warfarin cohort. After propensity score overlap weighting, warfarin initiation was associated with a higher rate of major bleeding than initiation of apixaban (hazard ratio [HR], 2.60; 95% CI, 1.51-4.49), including major gastrointestinal bleeding (HR, 2.99; 95% CI, 1.52-5.90). This association was intensified in the 71% of patients taking concurrent ART (major bleeding, HR, 6.68; 95% CI, 2.78-16.02; gastrointestinal bleeding, HR, 5.28; 95% CI, 2.08-13.42). Rivaroxaban vs apixaban was also associated with a higher rate of major bleeding (HR, 2.15; 95% CI, 1.18-3.94) and gastrointestinal bleeding (HR, 3.38; 95% CI, 1.57-7.25), with a stronger association in those using ART (major bleeding, HR, 4.83; 95% CI, 2.11-11.08; gastrointestinal bleeding, HR, 4.76; 95% CI, 1.78-12.70). Estimates were similar when comparing rivaroxaban with warfarin. No significant difference was observed in the rate of ischemic stroke or mortality among the 3 oral anticoagulants. Conclusions and Relevance This study found that in patients with HIV and AF, especially those treated with ART, warfarin and rivaroxaban were associated with higher rates of major bleeding compared with apixaban, suggesting a superior safety profile for apixaban in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsRivaroxabanHIV InfectionsWarfarinHemorrhageHumansFemaleMaleAgedPyrazolesPyridonesMiddle AgedUnited StatesAdministration, OralGastrointestinal Hemorrhage

Substanzen

AnticoagulantsRivaroxabanPyrazolesPyridonesapixabanWarfarin

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.

Zitieren

APA

Quinlan, C. M., Avorn, J., Kesselheim, A. S., Singer, D. E., Zhang, Y., Cervone, A., & Lin, K. J. (2025). Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.8335

Vancouver

Quinlan CM, Avorn J, Kesselheim AS, Singer DE, Zhang Y, Cervone A, et al. Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants. JAMA Internal Medicine. 2025. doi:10.1001/jamainternmed.2024.8335

BibTeX
@article{Quinlan2025,
  author = {Quinlan, Claire M and Avorn, Jerry and Kesselheim, Aaron S and Singer, Daniel E and Zhang, Yichi and Cervone, Alex and Lin, Kueiyu Joshua},
  title = {Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants},
  journal = {JAMA Internal Medicine},
  year = {2025},
  doi = {10.1001/jamainternmed.2024.8335}
}
Kostenlos starten →